
This phase I and zzso study of zzso in combination with zzso was performed to determine the maximum tolerated dose zzso and to evaluate safety and zzso in patients with zzso solid zzso 

zzso was administered as a zzso zzso zzso infusion followed 30 zzso later by zzso as a zzso h infusion, once every 21 zzso Up to two previous chemotherapy regimens were zzso Vitamin zzso supplementation and zzso acid were not included in this zzso 

zzso patients were treated in six escalating dose zzso zzso zzso at dose level 6 zzso 500 zzso plus zzso 130 zzso were zzso zzso grade zzso zzso and grade 3 zzso The zzso was not zzso The most common toxicity was zzso with grade zzso occurring in zzso of zzso The zzso of this zzso combination are consistent with those following zzso zzso Five responses (all zzso were observed over a broad range of solid zzso 

This zzso combination (without vitamin zzso every 21 days can be administered using full therapeutic doses of each agent with acceptable zzso and no overlapping zzso The recommended regimen for phase II studies is zzso 500 zzso plus zzso 120 zzso 

